Cargando…
利妥昔单抗追加治疗对初次完全缓解的弥漫大B细胞淋巴瘤患者的疗效评估
OBJECTIVE: To analyze the efficacy of additional two cycles of rituximab administration for Chinese patients with diffuse large B-cell lymphoma (DLBCL) in first complete remission (CR) after six cycles of standard 21-day rituximab plus cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHO...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
Editorial office of Chinese Journal of Hematology
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7342108/ https://www.ncbi.nlm.nih.gov/pubmed/27719717 http://dx.doi.org/10.3760/cma.j.issn.0253-2727.2016.09.006 |
Ejemplares similares
-
外科手术及利妥昔单抗对原发胃弥漫大B细胞淋巴瘤患者生存的影响
Publicado: (2016) -
Polatuzumab Vedotin联合利妥昔单抗和苯达莫司汀治疗复发/难治性弥漫大B细胞淋巴瘤的单中心疗效和安全性分析
Publicado: (2022) -
利妥昔单抗治疗特发性血栓性血小板减少性紫癜的临床研究
Publicado: (2015) -
剂量调整的EP(D)OCH方案联合利妥昔单抗治疗新诊断双表达淋巴瘤的疗效分析
Publicado: (2017) -
泽布替尼联合利妥昔单抗治疗伴CD79B及MYD88突变的原发皮肤弥漫大B细胞淋巴瘤,腿型1例
Publicado: (2023)